ERYTECH announces the completion of the enrollment of patients in its pivotal Phase III study in Acute Lymphoblastic Leukemia (ALL).
ERYTECH announces the completion of the enrollment of patients in its pivotal Phase III study in Acute Lymphoblastic Leukemia (ALL).